THC Finder
 
 
Hempcon
Los Angeles Santa Ana Long Beach San Diego San Francisco Seattle Denver Ann Arbor Detroit
Search Begin your search! Go
 
search Find My Location Go

Marijuana Blog

Germany launch for cannabis drug Sativex

Category: Medical Marijuana | Posted on Mon, July, 4th 2011 by THCFinder
GW Pharmaceuticals will today launch its cannabis-derived multiple sclerosis (MS) drug in Germany, which has the highest prevalence of MS in Europe.
 
Sativex contains active ingredients called 'cannabinoids' that are extracted from cannabis plants. It took GW around 10 years to develop the medicine, using genetically unique cannabis plants that are grown at a top-secret farm.
 
The Aim-listed business already sells Sativex, which treats muscle stiffness associated with MS, in Britain and Spain. GW said in May that in the nine months since launching in the UK, sales had reached around £2m.
 
Sativex contains active ingredients called 'cannabinoids' that are extracted from cannabis plants. It took GW around 10 years to develop the medicine, using genetically unique cannabis plants that are grown at a top-secret farm.
 
GW, with its marketing partner Almirall, is planning further European launches of Sativex and GW is also trialling the drug as a potential treatment in cancer pain. Last week, the company began a second Phase III trial of Sativex in cancer, in conjunction with Japan's Otsuka Pharmaceutical.
 
The company said today that muscle stiffness is a common symptom affecting around 80pc of the 130,000 MS patients in Germany.
 
0
Comments
 
Add Your Comments...

You must be Logged in to post comments!

No comments have been posted yet!

Search








Blog Categories

Popular Articles

Latest Offers In Your Area
Recent Blog Posts
Download Our App!
Green Queen Trichomes
May 18, 2013 | Category: Nugs
Bongs and grow books banned in Canada!
May 18, 2013 | Category: News
I want to stay the night here and get HIGH
May 18, 2013 | Category: Fun
Mobile Apps
Copyright 2013 THCFinder.com
All Rights Reserved.
About Us       Friends       API / Widgets       Privacy Policy       Terms of Use       Investors       Contact Us